NCT06995976 is a EARLY_PHASE1 clinical trial of 68Ga-dPNE in Malignant Tumour, sponsored by First Affiliated Hospital of Fujian Medical University.

Who is sponsoring NCT06995976?

NCT06995976 is sponsored by First Affiliated Hospital of Fujian Medical University.

What drugs are being tested in NCT06995976?

Interventions in NCT06995976: 68Ga-dPNE, 18F-FDG.

What condition does NCT06995976 study?

NCT06995976 studies Malignant Tumour.

Is NCT06995976 still recruiting?

NCT06995976 is currently recruiting now. Last updated 30 May 2025.

Last reviewed 2025-05-30 · How we verify

NCT06995976

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Recruiting now EARLY_PHASE1 Last updated 30 May 2025

What this trial tests

EARLY_PHASE1 trial testing 68Ga-dPNE in Malignant Tumour in 30 participants. Currently enrolling.

Timeline

1 March 2025

Primary endpoint
31 December 2025

1 March 2026

Quick facts

Lead sponsor	First Affiliated Hospital of Fujian Medical University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	1 March 2025
Primary completion	31 December 2025
Estimated completion	1 March 2026
Sites	1 location across China

Drugs / interventions tested

68Ga-dPNE — full drug profile →
18F-FDG — full drug profile →

Conditions studied

Malignant Tumour — all drugs for Malignant Tumour →

Sponsor

First Affiliated Hospital of Fujian Medical University

Who can join

Adults 18 to 90, any sex, with Malignant Tumour. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other First Affiliated Hospital of Fujian Medical University trials

Trials by the same sponsor.

NCT07513844 — Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease · NA · not yet recruiting
NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
NCT07369401 — Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory · NA · not yet recruiting
NCT07378358 — Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study · recruiting
NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06995976 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Fujian Medical University
Last refreshed: 30 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06995976.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing